Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms

Blood

Volumn 120, Issue 9, 2012, Pages 1933-1941

  Otsuru, Satoru ^a   Gordon, Patricia L ^b   Shimono, Kengo ^a   Jethva, Reena ^a   Marino, Roberta ^a,b   Phillips, Charlotte L ^c   Hofmann, Ted J ^a,b   Veronesi, Elena ^d   Dominici, Massimo ^d   Iwamoto, Masahiro ^a   Horwitz, Edwin M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c University of Missouri   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW MONONUCLEAR CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BONE MATRIX; CARTILAGE CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GROWTH ACCELERATION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MEDIATOR RELEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84865757197     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-400085     Document Type: Article

References (37)

1. Long MW, Robinson JA, Ashcraft EA, Mann KG. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors [published erratum appears in J Clin Invest. 1995;96(5):2541]. J Clin Invest. 1995;95(2):881-887.
2. Long MW, Williams JL, Mann KG. Expression of human bone-related proteins in the hematopoietic microenvironment. J Clin Invest. 1990;86(5):1387-1395.
3. Pereira RF, Halford KW, O'Hara MD, et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A. 1995;92(11):4857-4861.
4. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone. 1992;13(1):81-88.
5. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5(3):309-313.
6. Nilsson SK, Dooner MS, Weier HU, et al. Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J Exp Med. 1999;189(4):729-734.
7. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
8. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97(5):1227-1231.
9. Mehrotra M, Rosol M, Ogawa M, Larue AC. Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies. Exp Hematol. 2010;38(7):593-602.
10. Pereira RF, O'Hara MD, Laptev AV, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1998;95(3):1142-1147.
11. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99(13):8932-8937.
12. Dominici M, Pritchard C, Garlits JE, Hofmann TJ, Persons DA, Horwitz EM. Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci U S A. 2004;101(32):11761-11766.
13. Olmsted-Davis EA, Gugala Z, Camargo F, et al. Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A. 2003;100(26):15877-15882.
14. Ogawa M, Larue AC, Watson PM, Watson DK. Hematopoietic stem cell origin of connective tissues. Exp Hematol. 2010;38(7):540-547.
15. Dominici M, Tadjali M, Kepes S, et al. Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. Genesis. 2005;42(1):17-22.
16. Marino R, Martinez C, Boyd K, Dominici M, Hofmann TJ, Horwitz EM. Transplantable marrow osteoprogenitors engraft in discrete saturable sites in the marrow microenvironment. Exp Hematol. 2008;36(3):360-368.
17. Dominici M, Rasini V, Bussolari R, et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood. 2009;114(11):2333-2343.
18. Roberts-Pilgrim AM, Makareeva E, Myles MH, et al. Deficient degradation of homotrimeric type I collagen, alpha1(I)3 glomerulopathy in oim mice. Mol Genet Metab. 2011;104(3):373-382.
19. Yasuhara R, Yuasa T, Williams JA, et al. Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J Biol Chem. 2010;285(1):317-327.
20. Francois S, Bensidhoum M, Mouiseddine M, et al. Local irradiation induces not only homing of human mesenchymal stem cells (hMSC) at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution following irradiation damages. Stem Cells. 2006;24(4):1020-1029.
21. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 2002;46(12):3349-3360.
22. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45.
23. Dominici M, Marino R, Rasini V, et al. Donor cell-derived osteopoiesis originates from a selfrenewing stem cell with a limited regenerative contribution after transplantation. Blood. 2008;111(8):4386-4391.
24. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107(3):317-329.
25. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377-1385.
26. Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet. 1991;28(7):433-442.
27. Wang Q, Orrison BM, Marini JC. Two additional cases of osteogenesis imperfecta with substitutions for glycine in the alpha 2(I) collagen chain. A regional model relating mutation location with phenotype. J Biol Chem. 1993;268(33):25162-25167.
28. Chipman SD, Sweet HO, McBride DJ Jr, et al. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1993;90(5):1701-1705.
29. Rauch F. Bone growth in length and width: the yin and yang of bone stability. J Musculoskelet Neuronal Interact. 2005;5(3):194-201.
30. Horwitz EM, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10(8):771-774.
31. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250-2261.
32. Constantinou CO, Pack M, Young S, Prockop DJ. Phenotypic heterogeneity in osteogeneisi imperfecta: the mildly affected mother of a Proband with a lethal variant has the same mutation substituting cysteine for a1-glycine 904 in a type I procollagen gene (COL1A1). Am J Hum Genet. 1990;47(4):670-679.
33. Cabral WA, Fertala A, Green LK, Korkko J, Forlino A, Marini JC. Procollagen with skipping of alpha 1(I) exon 41 has lower binding affinity for alpha 1(I) C-telopeptide, impaired in vitro fibrillogenesis, and altered fibril morphology. J Biol Chem. 2002;277(6):4215-4222.
34. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71-74.
35. Pittenger MF, Mackay AM, Beck SC, et al. Multi-lineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.
36. Bhattacharya D, Rossi DJ, Bryder D, Weissman IL. Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning. J Exp Med. 2006;203(1):73-85.
37. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003;18(2):237-243.